Suratadenoturev

DB18672InvestigationalGene Therapies

Suratadenoturev is a gene-modified oncolytic adenovirus expressing the telomerase reverse transcriptase gene.

Mechanism
Curator reviewed
Also known as
A recombinant replication-competent adenovirus type 5 (Ad-5) in which the E1 gene, including its normal transcriptional regulatory element, has been deleted and replaced by an expression cassette containing an hTERT (human telomerase reverse transcriptas · A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively. · DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301) · Telomelysin · Telomerase Specific Replication-competent Oncolytic Adenovirus
Code names
OBP-301

Resolves to

Compound
UNIIFV0JG1SX76CAS1268642-13-2
Targets
O14746TERTQ13315ATMO60934NBNQ92878RAD50P49959MRE11

What you can answer from here — as of October 05, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Suratadenoturev, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In